Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Theravance Biopharma's retained earnings for the quarter that ended in Jun. 2026 was $-870.5 Mil.
Theravance Biopharma's quarterly retained earnings
declined
from Dec. 2025 ($-859.6 Mil) to Mar. 2026 ($-864.6 Mil) and
declined
from Mar. 2026 ($-864.6 Mil) to Jun. 2026 ($-870.5 Mil).
Theravance Biopharma's annual retained earnings
declined
from Dec. 2023 ($-909.1 Mil) to Dec. 2024 ($-965.5 Mil) but then
increased
from Dec. 2024 ($-965.5 Mil) to Dec. 2025 ($-859.6 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Theravance Biopharma Retained Earnings Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
What does a Retained Earnings of $-870.5 Mil mean?
Theravance Biopharma (TBPH) has a Retained Earnings of $-870.5 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Theravance Biopharma and its competitors.
Is Theravance Biopharma's Retained Earnings too high?
Theravance Biopharma's current Retained Earnings is $-870.5 Mil. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Retained Earnings compare to ABUS and SANA?
Theravance Biopharma's Retained Earnings of $-870.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Theravance Biopharma and its competitors. Theravance Biopharma's current Retained Earnings is $-870.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Fairly Valued. The stock's GF Value™ is $17.10, compared to a current price of $17.02 — trading 0.5% below its estimated fair value. The current Retained Earnings is $-870.5 Mil. Theravance Biopharma's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current Retained Earnings is $-870.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (TBPH) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of $17.02 is trading 0.5% below its estimated GF Value™ of $17.10.
GuruFocus considers Theravance Biopharma to be Fairly Valued.
Key valuation signals for TBPH:
Retained Earnings: $-870.5 Mil
GF Value™: $17.10 vs. price of $17.02 (0.5% below fair value)
No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for TBPH
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TBPH has been successfully added to your 
